Last updated Nov 3, 2026
A 42-year-old woman is diagnosed with invasive ductal breast cancer. Her sister was diagnosed with breast cancer at 39, and her maternal aunt died of pancreatic cancer at 58. Multi-gene panel testing identifies a pathogenic variant in PALB2.
AD (cancer predisposition); AR (Fanconi anemia subtype N)
- PALB2 (16p12.2): Partner And Localizer of BRCA2; loss-of-function variants, mostly truncating, rarely missense (p.Leu35Pro)
- Encodes a protein that links BRCA1 to BRCA2 at DNA breaks and is essential for BRCA2-mediated homologous recombination DNA repair
- Heterozygous pathogenic variants confer a moderate-to-high cancer predisposition
- Biallelic pathogenic variants cause Fanconi anemia complementation group N (FA-N), a severe childhood cancer predisposition syndrome
Cancer Risks (approximate lifetime):
| Cancer | Risk |
|---|---|
| Breast | 33-58% |
| Pancreatic | 2-3x general population |
| Ovarian | Modestly elevated |
PALB2 is the bridge in homologous recombination, the error-free repair of DNA double-strand breaks. Its N-terminal coiled-coil binds BRCA1, and its C-terminal WD40 domain binds BRCA2. Once a break is resected, BRCA1 recruits BRCA2 and the recombinase RAD51 through PALB2, so without PALB2 neither BRCA2 nor RAD51 is loaded at the break. PALB2 also binds DNA and RAD51 directly, and it acts in the Fanconi anemia pathway that repairs interstrand crosslinks.
That one role explains both conditions. One defective copy predisposes to breast and pancreatic cancer, with risk that varies by variant and population; the Finnish founder c.1592delT accounts for the high carrier rate there. Two defective copies cause Fanconi anemia group N. A truncation within the WD40 domain (p.Tyr1038Ter) exposes a hidden nuclear export signal and moves PALB2 out of the nucleus, away from the DNA it repairs.
Breast cancers in carriers are often high grade, and about 40% are triple negative. Tumors that have lost homologous recombination respond to platinum agents and PARP inhibitors, as BRCA-related tumors do.
- Moderate-to-high penetrance breast cancer gene
- Breast cancer risk is age-dependent and modified by family history
- Elevated pancreatic cancer risk (2-3x general population)
- Modestly elevated ovarian cancer risk (less well-defined than BRCA1/2)
- No clearly established association with prostate cancer
- Variable penetrance influenced by family history and other genetic modifiers
- Multi-gene panel testing (PALB2 is included on most hereditary breast cancer panels)
- Testing criteria are similar to BRCA1/2 (early-onset breast cancer, family history of breast or pancreatic cancer)
- NCCN guidelines now classify PALB2 as a high-penetrance gene warranting clinical action
- Enhanced breast surveillance: annual mammography plus breast MRI starting at age 30
- Discussion of risk-reducing mastectomy based on family history and individual risk assessment
- Pancreatic cancer screening (EUS/MRCP) if there is a family history of pancreatic cancer
- No specific ovarian cancer screening guidelines for PALB2 carriers at this time
- PARP inhibitors may be effective for PALB2-associated cancers (given role in homologous recombination)
- Cascade testing recommended for at-risk relatives
"PALB2 = PAncreatic & Breast": PALB2 increases risk for Pancreatic and Breast cancer. When you have your "PAL", the 2 ovaries are activated (modestly elevated ovarian cancer risk).
PALB2 is the Partner And Localizer of BRCA2: PALB2 colocalizes with BRCA2 for homologous recombination. Heterozygous (AD) = cancer predisposition; biallelic (AR) = Fanconi anemia subtype N.